Join
Live feed
·
PRReleasevia Quantisnow
Verastem Inc. logo

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

ByQuantisnow·Wall Street's wire, on your screen.
VSTM· Verastem Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VSTM (Verastem Inc.) and more on Quantisnow.